Loading Events

All Events

Harnessing Precision Medicine to Develop Novel Therapeutic Approaches for Neurodegenerative Disease

Our upcoming Founders at Work Speaker Series features Acurex Biosciences’ Co-Founder and CSO, Bill Shrader and VP of Biology, Sean Pintchovski. Acurex, a resident company at MBC BioLabs since 2020, is dedicated to fundamentally altering the course of Parkinson’s disease with novel therapeutics guided by a new generation of precision biomarkers. This promising approach will help usher in the first era of true precision medicine in neurology.

Our Speakers

Bill Shrader, PhD
Co-Founder and CSO

Bill Shrader is the Chief Scientific Officer and Co-founder of Acurex Biosciences and has an extensive background in developing small-molecule therapeutics and biomarkers for neurodegenerative conditions.

Sean Pintchovski, PhD
VP of Biology

Sean Pintchovski, PhD has 16+ years experience in the pharmaceutical industry. During this time, he successfully led pre-clinical research teams to discover, validate, and advance several small molecules into the clinic including PTC857 (GBA-Parkinson’s disease and Amyotrophic Lateral Sclerosis) and PTC743 (Friedreich’s Ataxia). Currently, Sean is leading a talented neuroscience team to develop novel therapeutic and precision biomarker-based ‘theragnostics’ (therapeutics combined with diagnostic biomarkers) for the treatment of neurodegenerative conditions, starting with Parkinson’s disease. He received a BS with Honors from the California Institute of Technology and earned his PhD in Neuroscience from the University of California, San Francisco.

Register:

RSVP July 2, 2024
First
Last
How did you hear about this event?

Feel free to share!

Go to Top